Should You Buy Actinium Pharmaceuticals, Inc. Stock in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Actinium Pharmaceuticals, Inc. (ATNM) occupies a solid middle-ground position with a Quality of Company score of 5.5/10. At the current market price of $0.88, the investment case depends heavily on whether our 13 independent valuation models indicate a discount to fair value.
The short answer: 8 of 9 CirclFi valuation models project upside for Actinium Pharmaceuticals, Inc. (ATNM) at $0.88 — the model consensus leans bullish, with a Quality Score of 5.5/10 and Value-Trap risk of 30/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.
Investment Thesis
The Bull Case
Target: $1.66 (+87.8% upside)
- According to the CirclFi Deep Alpha Valuation Engine, the stock shows multi-model upside with an average implied return of +25.2% across 7 bullish models from the current price of $0.88.
- According to the CirclFi Deep Alpha Valuation Engine, the Dynamic NAV model targets a fair value of $1.66 (+87.8%), anchoring the bull case with a methodology that provides a differentiated analytical lens.
- Industry tailwind: orphan drug designation could provide meaningful support for Actinium Pharmaceuticals, Inc. 's revenue and margin trajectory in the Pharmaceutical Preparations space.
The Bear Case
Target: $0.16 (-82.1%)
- According to the CirclFi Deep Alpha Valuation Engine, the First Chicago model sees the stock as overvalued with a fair value of $0.16 (-82.1%), suggesting that the market price embeds overly optimistic growth assumptions.
- According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +169.9% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology.
- Industry headwind: patent expiration revenue loss represents a meaningful risk for Actinium Pharmaceuticals, Inc. and its Pharmaceutical Preparations peers.
The Bottom Line
The convergence of 5.5/10 quality, multi-model undervaluation (7/9 bullish, +25.2% avg. upside), and a composite fair value of $1.11 vs. $0.88 current price makes Actinium Pharmaceuticals, Inc. one of the more compelling opportunities in our coverage. As always, our models provide a quantitative starting point — not a substitute for individual due diligence.
These are quantitative model outputs, not investment recommendations. Actinium Pharmaceuticals, Inc. 's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →
Frequently Asked Questions
Should I buy ATNM stock right now?
Based on CirclFi's multi-model analysis, 8 of 9 models see upside for ATNM at $0.88. The majority of models suggest the stock trades below fair value, but investors should weigh this against the Quality Score of 5.5/10 and individual risk tolerance. This is not a buy recommendation — see our full disclaimer.
What are the biggest risks of investing in Actinium Pharmaceuticals, Inc. ?
Key risks include: wide model disagreement (949% spread), signaling high uncertainty; general market and sector-specific risks affecting Pharmaceutical Preparations companies. Always diversify and consult a financial advisor.
How does ATNM compare to its competitors?
Among Pharmaceutical Preparations peers, ATNM holds a Quality Score of 5.5/10. Comparable companies include AMPH (QOC 10.0), AZN (QOC 10.0), CPRX (QOC 10.0). The relative ranking helps investors identify whether ATNM offers better fundamental quality than alternatives in the same sector.
Is ATNM a good long-term investment?
Long-term investment potential depends on fundamental quality and sustainable competitive advantages. ATNM's Quality Score of 5.5/10 suggests moderate fundamentals — not a clear long-term hold without further research into growth catalysts. Check our full data page for all 13 model estimates.
What price should I buy ATNM at?
CirclFi does not provide target buy prices or price alerts. However, our 9 active models produce fair value estimates ranging from $0.16 to $1.66. At $0.88, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.
Want the complete picture?
See all 13 model estimates, confidence scores, and the full valuation table for ATNM.
Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →
Buy with Gumroad